Creekmur Asset Management LLC Has $1.45 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Creekmur Asset Management LLC increased its stake in shares of DaVita Inc. (NYSE:DVA) by 1.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,852 shares of the company’s stock after purchasing an additional 163 shares during the quarter. Creekmur Asset Management LLC’s holdings in DaVita were worth $1,451,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. increased its position in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after purchasing an additional 78 shares in the last quarter. Family Firm Inc. acquired a new position in DaVita in the 2nd quarter valued at approximately $43,000. Versant Capital Management Inc increased its position in DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after acquiring an additional 155 shares during the period. Friedenthal Financial acquired a new position in DaVita in the 2nd quarter valued at approximately $48,000. Finally, Point72 Hong Kong Ltd acquired a new position in DaVita in the 2nd quarter valued at approximately $68,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have issued reports on DVA shares. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. TD Cowen upped their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Truist Financial upped their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, UBS Group increased their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $159.00.

Insider Buying and Selling

In related news, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 over the last ninety days. 2.00% of the stock is owned by corporate insiders.

DaVita Trading Down 6.2 %

DVA opened at $148.49 on Wednesday. DaVita Inc. has a twelve month low of $76.17 and a twelve month high of $168.50. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The company has a fifty day moving average of $158.40 and a 200-day moving average of $146.05. The stock has a market cap of $12.46 billion, a PE ratio of 16.86, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.85 earnings per share. On average, sell-side analysts predict that DaVita Inc. will post 9.99 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.